Menu Search
Equities

Inspire Medical Systems Inc

2DR:MUN

Inspire Medical Systems Inc

Actions
  • Price (EUR)215.70
  • Today's Change0.00 / 0.00%
  • Shares traded23.00
  • 1 Year change-11.60%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.

  • Revenue in USD (TTM)624.80m
  • Net income in USD-21.15m
  • Incorporated2007
  • Employees1.01k
  • Location
    Inspire Medical Systems Inc5500 Wayzata Blvd Ste 1600GOLDEN VALLEY 55416-1237United StatesUSA
  • Phone+1 (763) 957-5037
  • Fax+1 (302) 655-5049
  • Websitehttps://www.inspiresleep.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.